Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Extracellular vesicles in disease · Immunotherapy and Immune Responses · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Perforin and granzymes: function, dysfunction and human pathology10.1038/nri3839 ↗
2. An early history of T cell-mediated cytotoxicity10.1038/s41577-018-0009-3 ↗
3. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal10.1038/ni.1790 ↗
4. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition10.1126/science.aaf1292 ↗
5. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
6. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer10.1056/NEJMoa1200694 ↗
7. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma10.1056/NEJMoa1305133 ↗
8. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer10.1056/NEJMoa1507643 ↗
9. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma10.1056/NEJMoa2002788 ↗
10. Shedding light on the cell biology of extracellular vesicles10.1038/nrm.2017.125 ↗
11. Communication by extracellular vesicles: where we are and where we need to go10.1016/j.cell.2016.01.043 ↗
12. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer10.1038/nature22341 ↗
13. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy10.1038/s41467-019-11718-4 ↗
14. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles10.1016/j.matt.2020.05.017 ↗
15. Validation of the novel masseter muscle hypertrophy scale in Asian population10.1016/j.matt.2020.09.020 ↗
16. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells10.1080/20013078.2017.1324730 ↗
17. Exploiting exosomes in cancer liquid biopsies and drug delivery10.1002/adhm.201801268 ↗
18. Clinical cancer nanomedicine10.1016/j.nantod.2019.02.005 ↗
19. Apoptotic extracellular vesicles ameliorate multiple myeloma by restoring fas-mediated apoptosis10.1021/acsnano.1c03517 ↗
20. Embryonic stem cell derived small extracellular vesicles modulate regulatory T cells to protect against ischemic stroke10.1021/acsnano.1c00672 ↗
21. Immune cell-derived extracellular vesicles - functions and therapeutic applications10.1016/j.molmed.2019.02.003 ↗
22. Regulation of immune responses by extracellular vesicles10.1038/nri3622 ↗
23. Professional killers: the role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T‐cells and tumour cells10.1002/jev2.12075 ↗
24. IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8+ T cells10.1038/s41598-017-14000-z ↗
25. CTL-derived exosomes enhance the activation of CTLs stimulated by low-affinity peptides10.3389/fimmu.2019.01274 ↗
26. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth10.1016/j.cellimm.2020.104262 ↗
27. Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells10.1038/s41467-018-02865-1 ↗
28. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy10.18632/oncotarget.6175 ↗
29. Relationship between gut microbiota and circulating metabolites in population-based cohorts10.1038/s41467-019-13721-1 ↗
30. T-cell-mimicking nanoparticles for cancer immunotherapy10.1002/adma.202003368 ↗
31. T-cell-derived nanovesicles for cancer immunotherapy10.1002/adma.202101110 ↗
32. Re-engineering extracellular vesicles as smart nanoscale therapeutics10.1021/acsnano.6b07607 ↗
33. PD-1 blockade cellular vesicles for cancer immunotherapy
34. Vesicular antibodies: a bioactive multifunctional combination platform for targeted therapeutic delivery and cancer immunotherapy
35. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy10.7150/thno.48868 ↗
36. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy10.1021/acs.nanolett.9b00145 ↗
37. Equipping cancer cell membrane vesicles with functional DNA as a targeted vaccine for cancer immunotherapy10.1021/acs.nanolett.1c02582 ↗
38. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes10.1073/pnas.1521230113 ↗
39. Diacylglycerol kinase α regulates the formation and polarisation of mature multivesicular bodies involved in the secretion of Fas ligand-containing exosomes in T lymphocytes10.1038/cdd.2010.184 ↗
40. Metabolic competition in the tumor microenvironment is a driver of cancer progression10.1016/j.cell.2015.08.016 ↗
41. Isolation of exosomes and microvesicles from cell culture systems to study prion transmission10.1007/978-1-4939-6728-5_11 ↗
42. Isolation of extracellular vesicles: determining the correct approach (Review)10.3892/ijmm.2015.2194 ↗
43. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes10.1073/pnas.1521230113 ↗